1.Limited Clinical Significance of Splenectomy and Splenic Hilar Lymph Node Dissection for Type 4 Gastric Cancer
Aina KUNITOMO ; Kazunari MISAWA ; Yuichi ITO ; Seiji ITO ; Eiji HIGAKI ; Seiji NATSUME ; Takashi KINOSHITA ; Tetsuya ABE ; Koji KOMORI ; Yasuhiro SHIMIZU
Journal of Gastric Cancer 2021;21(4):392-402
Purpose:
Type 4 gastric cancer (GC) has a very poor prognosis even after curative resection, and the survival benefit of splenectomy for splenic hilar lymph node (LN; #10) dissection in type 4 GC remains equivocal. This study aimed to clarify the clinical significance of splenectomy for #10 dissection in patients with type 4 GC.
Materials and Methods:
The data of a total of 56 patients with type 4 GC who underwent total gastrectomy with splenectomy were retrospectively analyzed. Postoperative morbidity, state of LN metastasis, survival outcomes, and therapeutic value index (TVI) of each LN station were evaluated. TVI was calculated by multiplying the incidence of LN metastasis at each nodal station and the 5-year overall survival (OS) of patients who had metastasis to each node.
Results:
Overall, the postoperative morbidity rate was 28.6%, and the incidence of #10 metastasis in the patients was 28.6%. The 5-year OS rate for all patients was 29.9%, and most patients developed peritoneal recurrence. Moreover, the 5-year OS rates with and without #10 metastasis were 6.7% and 39.1% (median survival time, 20.4 vs. 46.0 months; P=0.006). The TVI of #10 was as low as 1.92.
Conclusions
The clinical significance of splenectomy in the dissection of #10 for type 4 GC is limited and splenectomy for splenic hilar dissection alone should be omitted.
2.Clinical Features and Treatment Outcome of Childhood Leukemia
Yuji MIYAJIMA ; Erika KITAMURA ; Yoko SHIBATA ; Chihiro HATANO ; Fumiko MIYAZAKI ; Sachie ITO ; Jun SAWAI ; Miyuki MAGOTA ; Kaname MATSUSAWA ; Tatsuya FUKAZAWA ; Koji TAKEMOTO ; Tetsuo KUBOTA ; Yuichi KATO ; Akimasa OGAWA ; Kuniyoshi KUNO
Journal of the Japanese Association of Rural Medicine 2011;60(4):527-534
We reviewed the clinical features and treatment outcome of 110 children with leukemia. Treatment was performed between 1980 and 2009 at our hospital. The mean age at onest was 5 years 6 months, the ratio of males to females was 1:0.72, and mean leukocyte count was 4.91×104/μl. Subtypes of leukemia were acute lymphoblastic leukemia (ALL) in 79.1% of the patients, acute myeloid leukemia (AML) in 17.2%, and chronic leukemia in 3.6%. In all patients, the overall 30-year survival rate estimated by the Kaplan-Meier method was 67.4%. In the three decades from the 1980s, the overall 10-year survival rate has been improved significantly from 46.4% in the 1980s, 69.2% in the 1990s to 87.2% in the 2000s (P<0.01). The overall 10-year survival rate was 70.7% in all children with ALL, and 70.6% in all children with AML. But in the last decade, the 10-year survival rate was improved to 87.0% in children with ALL and 87.3% in children with AML. Twenty-four patients received hematopoietic stem-cell transplantation, and the 10-year survival rate was 58.6% after transplant. Second malignancies were detected in three patients, and six patients have long-term sequelae. In conclusionn, the treatment result of childhood leukemia has improved considerably, so that more intensive treatment for patients with poor prognosis and less toxic treatment for patients with good prognosis will be necessary in future.
3.Prevalence of asthma and allergic rhinitis among adult population in Ulaanbaatar, Mongolia
Munkhbayarlakh SONOMJAMTS ; Sarangerel DASHDEMBEREL ; Narantsetseg LOGII ; Kimihiro NAKAE ; Yuichi CHIGUSA ; Shuji OHHIRA ; Clyde ITO ; Hironori SAGARA ; Sohei MAKINO
Asia Pacific Allergy 2014;4(1):25-31
BACKGROUND: Mongolia is changing lifestyle, unhealthy habits, increase of air pollution, increasing life expectancy have led to an up rise of chronic respiratory diseases. Over 10 years ago, the prevalence of asthma and allergic rhinoconjunctivitis in Mongolia were in the lower range reported from previous studies. OBJECTIVE: The main aim of the survey is to know the prevalence of asthma and allergic rhinitis among adult population of Ulaanbaatar city, Mongolia and their risk factors. METHODS: Total of approximately 1,200 adults aged 20 years and over were planned to be randomly selected. The questionnaire was developed on the basis of WHO Protocol for Assessment of Prevalence of Major Respiratory Diseases and modified by local risk factors assessment and by other international survey approach including Global Initiative for Asthma and European Community Respiratory Health Survey. RESULTS: Prevalence of current wheezer in all age group was 15.7% (95% CI: 14.7-16.8). Age and sex segregated distribution of current wheezer were defined among male and female and prevalence was 14.5% (95% CI: 13.3-16.2) in male and female 16.6% (95% CI: 15.2-18.3) respectively. Prevalence of diagnosed asthma among adults was 4.7% (95% CI: 4.3-5.6) in all age group, 3% (95% CI: 2.4-3.7) in male and 6.8% (95% CI: 5.8-7.9) in female. Prevalence of rhinoconjunctivitis was 14.6% in all age group. 28.4% out of subjects with allergic rhinitis has current asthma, while 11.6% of subjects without allergic rhinitis has asthma (p < 0.01). CONCLUSION: The prevalence of asthma increased for one decade in Ulaanbaatar. Prevalence of diagnosed asthma is approximately 5% and current wheezer is approximately 15% in adults of population, which is close to other Asia and European countries. Allergic rhinitis is a risk factor for asthma.
Adult
;
Air Pollution
;
Asia
;
Asthma
;
European Union
;
Female
;
Health Surveys
;
Humans
;
Life Expectancy
;
Life Style
;
Male
;
Mongolia
;
Prevalence
;
Rhinitis, Allergic
;
Risk Factors
4.Clinical and Imaging Features of Multiple System Atrophy: Challenges for an Early and Clinically Definitive Diagnosis
Hirohisa WATANABE ; Yuichi RIKU ; Kazuhiro HARA ; Kazuya KAWABATA ; Tomohiko NAKAMURA ; Mizuki ITO ; Masaaki HIRAYAMA ; Mari YOSHIDA ; Masahisa KATSUNO ; Gen SOBUE
Journal of Movement Disorders 2018;11(3):107-120
Multiple system atrophy (MSA) is an adult-onset, progressive neurodegenerative disorder. Patients with MSA show various phenotypes during the course of their illness, including parkinsonism, cerebellar ataxia, autonomic failure, and pyramidal signs. Patients with MSA sometimes present with isolated autonomic failure or motor symptoms/signs. The median duration from onset to the concomitant appearance of motor and autonomic symptoms is approximately 2 years but can range up to 14 years. As the presence of both motor and autonomic symptoms is essential for the current diagnostic criteria, early diagnosis is difficult when patients present with isolated autonomic failure or motor symptoms/signs. In contrast, patients with MSA may show severe autonomic failure and die before the presentation of motor symptoms/signs, which are currently required for the diagnosis of MSA. Recent studies have also revealed that patients with MSA may show nonsupporting features of MSA such as dementia, hallucinations, and vertical gaze palsy. To establish early diagnostic criteria and clinically definitive categorization for the successful development of disease-modifying therapy or symptomatic interventions for MSA, research should focus on the isolated phase and atypical symptoms to develop specific clinical, imaging, and fluid biomarkers that satisfy the requirements for objectivity, for semi- or quantitative measurements, and for uncomplicated, worldwide availability. Several novel techniques, such as automated compartmentalization of the brain into multiple parcels for the quantification of gray and white matter volumes on an individual basis and the visualization of α-synuclein and other candidate serum and cerebrospinal fluid biomarkers, may be promising for the early and clinically definitive diagnosis of MSA.
Biomarkers
;
Brain
;
Cerebellar Ataxia
;
Cerebrospinal Fluid
;
Dementia
;
Diagnosis
;
Early Diagnosis
;
Hallucinations
;
Humans
;
Multiple System Atrophy
;
Neurodegenerative Diseases
;
Paralysis
;
Parkinsonian Disorders
;
Phenotype
;
White Matter
5.An Update of Sports Medicine in Persons with Disabilities—Surviving Skeleton Muscles are Endocrine Organs—
Fumihiro TAJIMA ; Kazunari FURUSAWA ; Taro NAKAMURA ; Hidenobu OKUMA ; Yuichi UMEZU ; Makoto IDE ; Takashi MIZUSHIMA ; Mari UETA ; Takeshi NAKAMURA ; Takamitsu KAWAZU ; Hideki ARAKAWA ; Tomoyuki ITO ; Midori YAMANAKA ; Ken KOUDA ; Masaki GOTO ; Yusuke SASAKI ; Nami KANNO ; Takashi KAWASAKI ; Yasunori UMEMOTO ; Tomoya SHIMOMATSU ; Motohiko BANNO ; Hiroyasu UENISHI ; Hiroyuki OKAWA ; Ko ASAYAMA
The Japanese Journal of Rehabilitation Medicine 2010;47(5):304-309
6.Solution Proposal for 5 Challenges to be Resolved in Formalizing the Logical Format of Kampo-Based Diagnosis by Building Consensus Among 6 Medical Institutions Specialized in Kampo Herbal Medicine
Hiroshi ODAGUCHI ; Tatsuya ISHIGE ; Yuichi ITO ; Akino WAKASUGI ; Mariko SEKINE ; Toshihiko HANAWA ; Takao NAMIKI ; Shinichi MURAMATSU ; Makoto ARAI ; Tadamichi MITSUMA ; Yutaka SHIMADA ; Naotoshi SHIBAHARA ; Hideki ORIGASA
Kampo Medicine 2020;71(3):284-295
We are planning a study focused on the gathering of clinical data for the purpose of formalizing diagnostic logic at 6 institutions specialized in Kampo-based medical examinations. However, during the planning stage, it has been recognized that there are a large number of Kampo formulas to be studied, and differences among faculties and individuals exist regarding how to identify each Kampo formula, methods of gathering findings, and the evaluation of efficacy. Here we report the solution proposal reached after building consensus among all participating faculties on these issues. After raising the issues, conferences were held for each of them, until a unanimous consensus was obtained. As a result, the following conclusions were reached. Thirty-three Kampo formulas were selected as targets for the formalization of diagnostic logic. In addition, the range of dosage forms, crude drug ingredients, and permissible dosages for each Kampo formula were determined. Regarding clinical findings for these Kampo medicines, the items to be collected and evaluation criteria were also established. The criteria for evaluating the validity and safety of each Kampo medicine were decided, together with the grading and timing of evaluation. We hope that our solution proposal reached after building consensus becomes the basis for Kampo research in the future.